Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
Taramasso L, Di Biagio A, Riccardi N, Briano F, Di Filippo E, Comi L, Mora S, Giacomini M, Gori A, Maggiolo F. Taramasso L, et al. Among authors: comi l. PLoS One. 2019 Oct 11;14(10):e0223181. doi: 10.1371/journal.pone.0223181. eCollection 2019. PLoS One. 2019. PMID: 31603906 Free PMC article.
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry.
Galli L, Parisi MR, Poli A, Menozzi M, Fiscon M, Garlassi E, Francisci D, Di Biagio A, Sterrantino G, Fornabaio C, Degli Antoni A, Angarano G, Fusco FM, D'Arminio Monforte A, Corbelli GM, Santoro MM, Zazzi M, Castagna A; PRESTIGIO Study Group. Galli L, et al. Open Forum Infect Dis. 2020 Sep 26;7(11):ofaa456. doi: 10.1093/ofid/ofaa456. eCollection 2020 Nov. Open Forum Infect Dis. 2020. PMID: 33241063 Free PMC article.
Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial.
Maggiolo F, Gianotti N, Comi L, Di Filippo E, Fumagalli L, Nozza S, Galli L, Valenti D, Rizzi M, Castagna A. Maggiolo F, et al. Among authors: comi l. Antivir Ther. 2021 May;26(3-5):51-57. doi: 10.1177/13596535211042226. Epub 2021 Oct 27. Antivir Ther. 2021. PMID: 35485333 Clinical Trial.
Adherence to and Forgiveness of 3TC/DTG in a Real-World Cohort.
Maggiolo F, Valenti D, Teocchi R, Comi L, Filippo ED, Rizzi M. Maggiolo F, et al. Among authors: comi l. J Int Assoc Provid AIDS Care. 2022 Jan-Dec;21:23259582221101815. doi: 10.1177/23259582221101815. J Int Assoc Provid AIDS Care. 2022. PMID: 35695220 Free PMC article.
90 results